CMS Posts Stage 2 Clinical Quality Measures

At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

The FDA has approved a gene-editing therapy for sickle cell disease (SCD) for the first time.